DIA and NORD Convene Patients, Industry, Government, and Investors to Improve Orphan Product Research and Development

Share Article

DIA and the National Organization for Rare Disorders (NORD), in collaboration with FDA, NIH, EURORDIS, and the Duke Department of Pediatrics, will host the 2nd Annual US Conference on Rare Diseases & Orphan Products: Shaping the Future Now from October 22-24 in Washington, DC.

News Image
Bringing together all stakeholders—industry, regulatory, and academic professionals as well as patient organizations to facilitate the development of orphan products is a momentous occasion.

DIA and the National Organization for Rare Disorders (NORD), in collaboration with FDA, NIH, EURORDIS, and the Duke Department of Pediatrics, will host the 2nd Annual US Conference on Rare Diseases & Orphan Products: Shaping the Future Now from October 22-24 in Washington, DC. Patients, patient organizations, researchers, drug and device companies, investors, and government representatives will discuss the challenges facing orphan product development and access.

“It is always an honor to work with these esteemed organizations for a conference that impacts so many people,” states Paul Pomerantz, DIA Worldwide Executive Director. “Bringing together all stakeholders—industry, regulatory, and academic professionals as well as patient organizations to facilitate the development of orphan products is a momentous occasion.”

Three tracks: Research and Development, Policy, and Special Challenges in Rare Diseases will feature sessions on:

  •     Cystic Fibrosis and Comprehensive Approaches to Therapy Development
  •     Small Clinical Trials
  •     Working with FDA
  •     The Challenges of Reimbursement for the Rare Disease Patient
  •     Impact of FDASIA on Orphan Product Development
  •     Risk Tolerance for the Rare Disease Patient

“Now in its 2nd year, this conference facilitates dialogue for those involved in orphan product development,” explains Peter L. Saltonstall, President and CEO of NORD. “From patients and patient advocates to government representatives to medical researchers and industry professionals, all the key stakeholders will be in attendance to discuss ways to overcome the economic and regulatory challenges of orphan product development.”

Register for the US Conference on Rare Diseases & Orphan Products: Shaping the Future Now by October 1 to save!

Follow #DIARAREDISEASES on Twitter for real-time updates.

About DIA
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; and Beijing, China. http://www.diahome.org. Follow DIA on Facebook, Twitter, LinkedIn, and YouTube.

About NORD
The National Organization for Rare Disorders (NORD), a 501(c)(3) organization, is a unique federation of voluntary health organizations dedicated to helping people with rare "orphan" diseases and assisting the organizations that serve them. NORD is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and service. http://www.rarediseases.org. Follow NORD on Facebook, Twitter, LinkedIn, and YouTube.

Contacts:
Christine Tarlecki
DIA
+1-215-442-6154
Christine.Tarlecki(at)diahome(dot)org

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Christine Tarlecki
Visit website